Professor Johanna Olweus and her research team of 16 have received NOK 4.5 million in grants from the Danish Novo Nordisk Foundation. The money will be used to commercialize a whole new type of cancer immunotherapy that Olweus and her team are developing.
They have found a way to program cancer patients' immune cells to fight cancer using healthy human immune cells. This method allows the immune system to attack the cancer cells specifically, without harming other cells.
Published in major journals, first or last author from Oslo University Hospital.
Tenecteplase for acute ischaemic stroke
Lancet (in press)
The association of prison security level with mortality after release from prison: a retrospective national cohort study (2000-16)
Lancet Public Health, 7 (7), e583-e592
Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial
Lancet, 399 (10344), 2398-2411